Mandibular Device Comparable to CPAP to Reduce BP Mandibular Device Comparable to CPAP to Reduce BP
A mandibular advancement device was non-inferior to standard of care CPAP to reduce blood pressure in patients with hypertension and sleep apnea in the CRESCENT trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 7, 2024 Category: Cardiology Tags: Cardiology Source Type: news
Long-Awaited RCT Data Show Survival Benefit With Impella CP: DanGer Shock
The results, specific to STEMI patients with cardiogenic shock, are striking, experts say, but much work lies ahead. ATLANTA, GA—For patients with acute MI complicated by cardiogenic shock (AMICS), the routine use of mechanical circulatory support (MCS) with the Impella CP (Abiomed) microaxial…#atlanta #amics #impellacpabiomed #dangershock #jacobeifermøller #phd #denmark #acc #nejm #sunilvrao (Source: Reuters: Health)
Source: Reuters: Health - April 7, 2024 Category: Consumer Health News Source Type: news
Massachusetts city is set to settle a lawsuit in the death of an opioid-addicted woman
Relatives of a Vermont woman whose obituary drew national attention for its candid and heart-breaking discussion of her opioid addiction appear to have reached a settlement in a lawsuit over her death (Source: ABC News: Health)
Source: ABC News: Health - April 7, 2024 Category: Consumer Health News Tags: Health Source Type: news
Impella CP Improves Survival in STEMI, Cardiogenic Shock Impella CP Improves Survival in STEMI, Cardiogenic Shock
Use of a microaxial flow pump led to a lower risk of death in patients with STEMI-related cardiogenic shock in the DanGer Shock trial, although with more adverse events.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 7, 2024 Category: Cardiology Tags: Cardiology Source Type: news
Impella Saves Live in CS, but Patient Selection Key Impella Saves Live in CS, but Patient Selection Key
In the first randomized trial of Impella in a select group of patients with AMI and cardiogenic shock, the device saved lives. The high rate of serious adverse events calls us to pay attention to the nuances of the data, says John Mandrola, MD.theheart.org on Medscape (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - April 7, 2024 Category: Intensive Care Tags: Cardiology Commentary Source Type: news
Impella Saves Lives in CS, but Patient Selection Key Impella Saves Lives in CS, but Patient Selection Key
In the first randomized trial of Impella in a select group of patients with AMI and cardiogenic shock, the device saved lives. The high rate of serious adverse events calls us to pay attention to the nuances of the data, says John Mandrola, MD.theheart.org on Medscape (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - April 7, 2024 Category: Emergency Medicine Tags: Cardiology Commentary Source Type: news
Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension
The KARDIA-2 study met its primary endpoint demonstrating additive, placebo-adjusted systolic blood pressure reductions of up to 12.1 mmHgat month three. These results were statistically significant and clinically meaningfulZilebesiran demonstrated an encouraging safety and tolerability profile when added to standard of care antihypertensives Basel, 7 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam today released detailed results from the Phase II KARDIA-2 study evaluating the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard of care (SOC) antihypertensives. T...
Source: Roche Investor Update - April 7, 2024 Category: Pharmaceuticals Source Type: news
Chef Jos é Andrés Breaks Down in Heart Wrenching ABC Interview About His Aid Workers Killed By Israeli Drone Strike: ‘I Will Forever Have to Live With This’
Chef José Andrés broke down in tears Sunday while remembering the seven lost volunteers from his World Central Kitchen in separate IDF missile strikes. He spoke with ABC’s Martha Raddatz, who filled in on This Week With George Stephanopoulos. “I’m still going through the process, but there’s a lot…#joséandrés #worldcentral #abc #martharaddatz #georgestephanopoulos #damiansoból #raddatz #wck #abcnews #israeli (Source: Reuters: Health)
Source: Reuters: Health - April 7, 2024 Category: Consumer Health News Source Type: news
Proof of Benefit in Acute MI Again Evades an SGLT2 Inhibitor
(MedPage Today) -- ATLANTA -- The SGLT2 inhibitor empagliflozin (Jardiance) did not exactly prevent deaths and heart failure (HF) events when initiated atop other standard therapies for acute myocardial infarction (MI), the EMPACT-HF trial found... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 7, 2024 Category: Cardiology Source Type: news
Cardiology's Bid to Defect From ABIM Plows Ahead
(MedPage Today) -- ATLANTA -- Cardiology's bid to escape what many see as burdensome requirements for board certification maintenance under the American Board of Internal Medicine (ABIM) is well underway, a panel reported at the American College... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 7, 2024 Category: American Health Source Type: news
Dogecoin Rally Intensifies: Eyes Set On Historic New Highs
After a retracement from its current high of $0.22960, the price of Dogecoin (DOGE) looks like it is not yet done as the memecoin bounced back and moving toward its current high. Dogecoin Price Technical Analysis Dogecoin is one of the few memecoins that have captured the hearts of many crypto…#dogecoin #shibainu #rsi #upwardmovement (Source: Reuters: Health)
Source: Reuters: Health - April 7, 2024 Category: Consumer Health News Source Type: news
Interatrial Shunt's Prospects in Heart Failure Shrink After RELIEVE-HF
(MedPage Today) -- ATLANTA -- An interatrial shunt failed to provide a clinical benefit to people with heart failure (HF) overall in the RELIEVE-HF trial, though actual harm or benefit seemed to hinge on the patient's left ventricular ejection... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 7, 2024 Category: Cardiology Source Type: news
Wegovy ’s heart benefits are not just linked with weight loss, new study suggests
(Source: Reuters: Health)
Source: Reuters: Health - April 7, 2024 Category: Consumer Health News Source Type: news
Empagliflozin Fails to Reduce Events After Acute MI Empagliflozin Fails to Reduce Events After Acute MI
Empagliflozin did not significantly reduce overall HF hospitalization or all-cause death in high-risk patients in EMPACT-MI but did reduce first and total hospitalizations.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 6, 2024 Category: Consumer Health News Tags: Cardiology Source Type: news
Miracle diabetes jab Ozempic 'halves severe heart failure symptoms' in 'paradigm shift' in battle against deadly condition
Celebrities like Elon Musk (pictured) have admitted to taking the miracle diabetes jab Ozempic in a bid to slim down. (Source: the Mail online | Health)
Source: the Mail online | Health - April 6, 2024 Category: Consumer Health News Source Type: news
